title: [Hypertension and stroke: new publications in 2005].
abstract: Current studies confirm the previous European recommendations according to which the individual evaluation of the patient's risk is superior to a breakdown into general therapeutic groups. Studies on primary prevention show that patients with atrial fibrillation in particular obtain greater benefit from losartan than from atenolol, and that even a small reduction in blood pressure reduced the stroke risk. The greatest benefit was seen in those patients in whom the target pressure was achieved within a period of six months. The combination of a calcium antagonist and an ACE inhibitor prevented significantly more strokes than the combination of a beta blocker and a diuretic. In studies investigators secondary prevention a sartan was found to prevent more cardiovascular events than nitrendipine.
authors.affiliation: Medizinische Klinik, St.-Josefs-Hospital, Cloppenburg. j.schrader@kh-clp.de
authors.forename: J
authors.initials: J
authors.lastname: Schrader
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects; D003430:Cross-Sectional Studies; D004359:Drug Therapy, Combination; D019317:Evidence-Based Medicine; D006801:Humans; D006973:Hypertension / Q000188:drug therapy / Q000453:epidemiology*; D009203:Myocardial Infarction / Q000453:epidemiology / Q000517:prevention & control; D017410:Practice Guidelines as Topic; D012016:Reference Values; D012307:Risk Factors; D020521:Stroke / Q000453:epidemiology* / Q000517:prevention & control
chemical_list: D000959:Antihypertensive Agents